NGM·Healthcare·$2.1B·#28 / 520 in Healthcare
AUPH Aurinia Pharmaceuticals Inc
76SOLID
CATEGORY BREAKDOWN
GROWTH33
QUALITY99
STABILITY97
VALUATION61
GOVERNANCE64
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+20.4%
33
> 50% strong
Gross Margin
Revenue retained after direct costs
88.5%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
12.9%
90
< 25% strong
Price / Sales
Market cap relative to trailing revenue
6.8x
61
< 3x strong
Rule of 40
Growth rate plus operating margin
58
98
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
6.6%
48
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+0.9%
94
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE AUPH WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when AUPH's score changes by 5+ points.
DATA INFO
Last updated: Sep 2, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.